Precision-Cut Liver Slices for Bipotent Stem Cell Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying bipotent liver stem cells in vitro are complex, introduce variability, and fail to accurately simulate the liver microenvironment, particularly in precision-cut liver slice (PCLS) systems which lack these cells.
Innovation Solution
A method involving precision-cut liver slices (PCLS) cultured in a specific medium with additives like B27 supplement, EGF, FGF10, HGF, RSPO1, and Wnt3a, which supports the generation and activation of bipotent liver stem cells, maintaining the liver's multicellular architecture and physiological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional in vitro methods (2D/3D cell cultures, organoids, tissue engineering) are used to study bipotent liver stem cells, then the study can be performed in controlled conditions, but the methods introduce great variability between samples and fail to accurately simulate the liver microenvironment
Solution Approach 1:
The patent uses precision-cut liver slices (PCLS) that are ex vivo copies of native liver tissue, preserving the original three-dimensional architecture and cellular composition. This copying approach maintains the authentic liver microenvironment without requiring complex in vitro reconstruction systems, thereby improving simulation accuracy while reducing system complexity.
Solution Approach 2:
The liver tissue is segmented into thin precision-cut slices (PCLS) that can be cultured individually while maintaining their native three-dimensional structure. This segmentation allows the complex liver tissue to be studied in controlled cultures without losing its architectural integrity, resolving the contradiction between maintainability and microenvironment fidelity.
2Stability of the object's composition
If precision-cut liver slices (PCLS) are used to maintain native liver structure, then the three-dimensional structure and histological cell organization are preserved, but PCLS do not contain liver stem cells and cannot be used to study their activation
Solution Approach 1:
The patent applies preliminary action by treating PCLS with specific culture conditions (including Wnt3a, FGF10, HGF, and other growth factors) before stem cell activation occurs. This preliminary preparation creates the appropriate microenvironment and signaling conditions that trigger and support stem cell activation while preserving the native tissue architecture throughout the experiment.
Solution Approach 2:
The patent uses growth factors and cytokines (Wnt3a, FGF10, HGF, EGF, RSPO1, noggin) as intermediary substances that mediate between the preserved native architecture and the activation of liver stem cells. These intermediaries enable stem cell activation without disrupting the three-dimensional tissue structure, resolving the contradiction between structural preservation and functional activation.
3Productivity
If complex culture media with multiple growth factors are used to activate stem cells, then stem cell generation is enhanced, but the culture system becomes more complex and costly
Solution Approach 1:
The patent optimizes parameter changes by systematically adjusting the concentration and combination of growth factors (Wnt3a, FGF10, HGF, EGF, RSPO1, noggin) in the culture medium. By fine-tuning these parameters, the patent achieves enhanced stem cell generation efficiency while maintaining a manageable culture system complexity that can be standardized for research applications.
Data Source
Figure 1a~1c
Figure 2a~2b
Figure 3a
AI summary
The subject of the present invention is an in vitro method for generation of bipotent liver stem cells in liver tissue sections in PCLS (Precision-cut Liver Slice) form in culture. A further subject of the invention is a culture medium for PCLS of human or mouse origin and the use thereof to stimulate liver stem-cell generation in liver tissue cultures.